PinneyAssociates, a science-based health consulting firm, has named Judy Ashworth, MD as its new chief medical officer and Bernie Simone as its new vice president, Client Strategy and Rx-to-OTC Switch (the transfer of proven prescription drugs to non-prescription status), it was reported on Monday.
Ashworth has around two decades of experience in the development of novel analgesics and abuse-deterrent formulations. While at Grunenthal GmbH, she led the clinical team during the EU and US regulatory submission and approval of tapentadol and most recently was head of its EU Innovative Medicines Unit hub in Leiden, Netherlands.
Simone has more than 30 years of experience in the OTC industry, including in Rx-to-OTC Switch, product marketing, and business development. While at Sanofi Consumer Healthcare, he led the first-in-class switch of Nasacort Allergy 24HR and the switch of Xyzal Allergy 24HR. While at Bayer, he held several positions including director roles in business development, marketing and global category management. He led high growth strategic initiatives for the Aleve and Alka-Seltzer franchises, as well as global CardioAspirin, and multiple Rx-to-OTC switch initiatives. His experience includes more than 40 therapeutic categories in OTC medicines, prescription drugs, medical devices and dietary supplements.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary